• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3: New insider Newtyn Management, Llc claimed ownership of 5,900,000 shares

    11/23/21 6:57:24 PM ET
    $FLXN
    Major Pharmaceuticals
    Health Care
    Get the next $FLXN alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Newtyn Management, LLC

    (Last) (First) (Middle)
    60 EAST 42ND STREET
    9TH FLOOR

    (Street)
    NEW YORK NY 10165

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    11/18/2021
    3. Issuer Name and Ticker or Trading Symbol
    Flexion Therapeutics Inc [ FLXN ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Common Stock, par value $0.001 per share 5,900,000 I See footnote(1)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. The shares are held directly by Newtyn Partners, LP ("NP") and Newtyn TE Partners, LP ("NTE"). Newtyn Management, LLC, as the investment manager to NP and NTE, possesses the sole power to direct the vote and the sole power to direct the disposition of the securities held by NP and NTE. Newtyn Management, LLC disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, NP, NTE or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
    /s/ Eugene Dozortsev 11/23/2021
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $FLXN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FLXN

    DatePrice TargetRatingAnalyst
    11/19/2021Outperform → Market Perform
    Northland Capital Markets
    10/19/2021$25.00 → $10.00Buy → Neutral
    HC Wainwright & Co.
    10/12/2021$20.00 → $12.00Outperform → Market Perform
    BMO Capital
    10/12/2021Strong Buy → Market Perform
    Raymond James
    10/12/2021$14.00 → $10.00Outperform → Neutral
    Credit Suisse
    8/6/2021$8.00 → $6.00Neutral
    Goldman Sachs
    8/5/2021$20.00 → $18.00Buy
    Needham
    More analyst ratings

    $FLXN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Avilar Therapeutics Appoints Adam Muzikant, PhD, as Chief Business Officer

      Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced the appointment of Adam Muzikant, PhD, as Chief Business Officer. Dr. Muzikant brings 18 years of business development experience creating and executing value-creating deals, from platform collaborations to commercial-stage product licenses and M&A, across a range of therapeutic areas and technologies at both private and public biopharmaceutical companies. In his role at Avilar, Dr. Muzikant will be responsible for corporate and business development as well as various business operations functions. This press release features multimedia. View the full release here: https://www.busi

      6/15/22 8:00:00 AM ET
      $FLXN
      Major Pharmaceuticals
      Health Care
    • Pacira BioSciences Completes Acquisition of Flexion Therapeutics and Strengthens Leadership Position in Non-Opioid Pain Management

      -- Adds highly complementary ZILRETTA® to Pacira commercial offering -- -- Combined portfolio offers end-to-end non-opioid solutions along the pain pathway -- TAMPA, Fla. and BURLINGTON, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced the completion of its previously announced acquisition of Flexion Therapeutics, Inc. (NASDAQ:FLXN). "This is an exciting day for Pacira BioSciences as this acquisition expands our industry leadership and marks a major milestone in our strategy to build a robust offering of novel, non-opioid treatments to im

      11/19/21 8:40:10 AM ET
      $FLXN
      $PCRX
      Major Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain Management

      -- Adds highly complementary ZILRETTA® to Pacira commercial offering -- -- Combined portfolio offers end-to-end non-opioid solutions along the pain pathway -- -- Further enhances topline revenue growth; provides attractive potential synergies and expected to be accretive to full-year 2022 earnings and significantly accretive thereafter -- -- Pacira to host conference call today at 8:30 AM ET -- TAMPA, Fla. and BURLINGTON, Mass., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, and Flexion Therapeutics, Inc. (NASDAQ:FLXN) today announced a definitive agreement

      10/11/21 7:00:00 AM ET
      $FLXN
      $PCRX
      Major Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $FLXN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Newtyn Management, Llc

      4 - Flexion Therapeutics Inc (0001419600) (Issuer)

      11/23/21 7:00:12 PM ET
      $FLXN
      Major Pharmaceuticals
      Health Care
    • SEC Form 3: New insider Newtyn Management, Llc claimed ownership of 5,900,000 shares

      3 - Flexion Therapeutics Inc (0001419600) (Issuer)

      11/23/21 6:57:24 PM ET
      $FLXN
      Major Pharmaceuticals
      Health Care
    • SEC Form 4: Stejbach Mark returned $107,364 worth of shares to the company (12,631 units at $8.50), closing all direct ownership in the company to cover taxes

      4 - Flexion Therapeutics Inc (0001419600) (Issuer)

      11/19/21 10:20:34 AM ET
      $FLXN
      Major Pharmaceuticals
      Health Care

    $FLXN
    Financials

    Live finance-specific insights

    See more
    • Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain Management

      -- Adds highly complementary ZILRETTA® to Pacira commercial offering -- -- Combined portfolio offers end-to-end non-opioid solutions along the pain pathway -- -- Further enhances topline revenue growth; provides attractive potential synergies and expected to be accretive to full-year 2022 earnings and significantly accretive thereafter -- -- Pacira to host conference call today at 8:30 AM ET -- TAMPA, Fla. and BURLINGTON, Mass., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, and Flexion Therapeutics, Inc. (NASDAQ:FLXN) today announced a definitive agreement

      10/11/21 7:00:00 AM ET
      $FLXN
      $PCRX
      Major Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Flexion Therapeutics Reports Second-Quarter 2021 Financial Results and Recent Business Highlights

      ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales were $28.2 million in Q2 2021, reflecting growth of 15% over the previous quarterNet loss in Q2 2021 decreased by $10.4 million (32%), as compared to Q2 2020, during the height of the COVID-19 impact on ZILRETTA salesCompany extends estimated cash runway into 2023 by refinancing term loanFlexion reiterates full-year 2021 ZILRETTA net sales guidance in the range of $120 million to $130 millionData for FX301 bunionectomy study and FX201 single ascending dose/expansion knee osteoarthritis (OA) study anticipated by year-endConference call to be held today at 4:30 pm BURLINGTON, Mass., Aug. 04, 2021 (GLOBE NEW

      8/4/21 4:01:00 PM ET
      $FLXN
      Major Pharmaceuticals
      Health Care
    • Flexion Therapeutics to Report Second-Quarter 2021 Financial Results on August 4, 2021

      BURLINGTON, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) today announced that it will report its second-quarter 2021 financial results after the close of the U.S. financial markets on Wednesday, August 4, 2021 at 4:30 p.m. ET. A live webcast of the conference call can be accessed through the "Investors" tab on the Flexion Therapeutics website, and a replay will be available online after the call. For those planning to ask a question, the dial-in number for the conference call is 855-770-0022 for domestic participants and 908-982-4677 for international participants, with Conference ID # 3846257. Please dial in at least 15 minutes in advance to ensure

      7/29/21 4:15:00 PM ET
      $FLXN
      Major Pharmaceuticals
      Health Care

    $FLXN
    SEC Filings

    See more
    • SEC Form 15-12B filed by Flexion Therapeutics, Inc.

      15-12B - Flexion Therapeutics Inc (0001419600) (Filer)

      11/29/21 4:15:36 PM ET
      $FLXN
      Major Pharmaceuticals
      Health Care
    • SEC Form EFFECT filed by Flexion Therapeutics, Inc.

      EFFECT - Flexion Therapeutics Inc (0001419600) (Filer)

      11/26/21 12:15:07 AM ET
      $FLXN
      Major Pharmaceuticals
      Health Care
    • SEC Form S-8 POS filed by Flexion Therapeutics, Inc.

      S-8 POS - Flexion Therapeutics Inc (0001419600) (Filer)

      11/19/21 9:29:02 AM ET
      $FLXN
      Major Pharmaceuticals
      Health Care

    $FLXN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Flexion Therapeutics, Inc. (Amendment)

      SC 13G/A - Flexion Therapeutics Inc (0001419600) (Subject)

      11/9/21 3:34:00 PM ET
      $FLXN
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed by Flexion Therapeutics, Inc. (Amendment)

      SC 13G/A - Flexion Therapeutics Inc (0001419600) (Subject)

      5/10/21 2:23:01 PM ET
      $FLXN
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Flexion Therapeutics Inc (0001419600) (Subject)

      2/16/21 12:45:30 PM ET
      $FLXN
      Major Pharmaceuticals
      Health Care

    $FLXN
    Leadership Updates

    Live Leadership Updates

    See more
    • Avilar Therapeutics Appoints Adam Muzikant, PhD, as Chief Business Officer

      Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced the appointment of Adam Muzikant, PhD, as Chief Business Officer. Dr. Muzikant brings 18 years of business development experience creating and executing value-creating deals, from platform collaborations to commercial-stage product licenses and M&A, across a range of therapeutic areas and technologies at both private and public biopharmaceutical companies. In his role at Avilar, Dr. Muzikant will be responsible for corporate and business development as well as various business operations functions. This press release features multimedia. View the full release here: https://www.busi

      6/15/22 8:00:00 AM ET
      $FLXN
      Major Pharmaceuticals
      Health Care
    • Flexion Therapeutics Announces Appointment of Utpal Koppikar to its Board of Directors

      BURLINGTON, Mass., July 12, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) today announced the appointment of Utpal Koppikar, Chief Financial Officer of Atara Biotherapeutics, to its Board of Directors. Mr. Koppikar will serve as the chair of Flexion's audit committee. "I am thrilled to welcome Utpal to Flexion's Board, as his extensive financial experience leading biotechnology companies makes him an outstanding addition to our Board of Directors," said Michael Clayman, MD, President and Chief Executive Officer of Flexion Therapeutics. "In addition to Utpal's anticipated contributions guiding our corporate strategy, I look forward to his stewardship and counsel as chai

      7/12/21 4:30:00 PM ET
      $FLXN
      Major Pharmaceuticals
      Health Care
    • Flexion Therapeutics Announces Appointment of William T. Andrews, M.D., F.A.C.P., as Chief Medical Officer

      BURLINGTON, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that William T. Andrews, M.D., F.A.C.P., will join the company as Chief Medical Officer (CMO), effective July 1, 2021. "Will brings an impressive combination of medical, clinical, regulatory and corporate development skills, complemented by deep commercial experience he gained launching seven products throughout his career,” said Michael Clayman, MD, President and Chief Executive Officer of Flexion Therapeutics. “He will play an integral role in building and strengthening our organization, and we could not be more excited to welcome him to our senior management team.” "I have be

      6/9/21 4:15:00 PM ET
      $FLXN
      Major Pharmaceuticals
      Health Care

    $FLXN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Flexion Therapeutics downgraded by Northland Capital Markets

      Northland Capital Markets downgraded Flexion Therapeutics from Outperform to Market Perform

      11/19/21 8:56:45 AM ET
      $FLXN
      Major Pharmaceuticals
      Health Care
    • Flexion Therapeutics downgraded by HC Wainwright & Co. with a new price target

      HC Wainwright & Co. downgraded Flexion Therapeutics from Buy to Neutral and set a new price target of $10.00 from $25.00 previously

      10/19/21 6:23:51 AM ET
      $FLXN
      Major Pharmaceuticals
      Health Care
    • Flexion Therapeutics downgraded by BMO Capital with a new price target

      BMO Capital downgraded Flexion Therapeutics from Outperform to Market Perform and set a new price target of $12.00 from $20.00 previously

      10/12/21 7:24:34 AM ET
      $FLXN
      Major Pharmaceuticals
      Health Care